250 related articles for article (PubMed ID: 30520145)
81. JAK inhibition in inflammatory bowel disease.
Olivera P; Danese S; Peyrin-Biroulet L
Expert Rev Clin Immunol; 2017 Jul; 13(7):693-703. PubMed ID: 28164724
[TBL] [Abstract][Full Text] [Related]
82. JAK inhibitors in psoriasis: a promising new treatment modality.
Kwatra SG; Dabade TS; Gustafson CJ; Feldman SR
J Drugs Dermatol; 2012 Aug; 11(8):913-8. PubMed ID: 22859235
[TBL] [Abstract][Full Text] [Related]
83. The use of tofacitinib in the treatment of inflammatory bowel disease.
Weisshof R; Golan MA; Yvellez OV; Rubin DT
Immunotherapy; 2018 Aug; 10(10):837-849. PubMed ID: 29701124
[TBL] [Abstract][Full Text] [Related]
84. Factors associated with insurance coverage of tofacitinib for alopecia areata: A retrospective review from an academic institution.
Thompson HJ; Vavra T; Jabbari A
J Am Acad Dermatol; 2020 Nov; 83(5):1509-1510. PubMed ID: 32553634
[No Abstract] [Full Text] [Related]
85. Jakpot! New small molecules in autoimmune and inflammatory diseases.
Ghoreschi K; Gadina M
Exp Dermatol; 2014 Jan; 23(1):7-11. PubMed ID: 24131352
[TBL] [Abstract][Full Text] [Related]
86. Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen.
Chen YY; Lin SY; Chen YC; Yang CC; Lan CE
Eur J Dermatol; 2019 Dec; 29(6):667-669. PubMed ID: 31903968
[No Abstract] [Full Text] [Related]
87. The use of Tofacitinib in the treatment of inflammatory bowel disease.
Nasonov EL; Abdulganieva DI; Fairushina IF
Ter Arkh; 2019 Mar; 91(2):101-108. PubMed ID: 31094180
[TBL] [Abstract][Full Text] [Related]
88. Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: A case series.
Park HS; Kim MW; Lee JS; Yoon HS; Huh CH; Kwon O; Cho S
J Am Acad Dermatol; 2017 Nov; 77(5):978-980. PubMed ID: 29029911
[No Abstract] [Full Text] [Related]
89. [Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis].
Sonomoto K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):443-7. PubMed ID: 27118331
[TBL] [Abstract][Full Text] [Related]
90. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis.
Craiglow BG; King BA
J Invest Dermatol; 2014 Dec; 134(12):2988-2990. PubMed ID: 24940651
[No Abstract] [Full Text] [Related]
91. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.
Jabbari A; Dai Z; Xing L; Cerise JE; Ramot Y; Berkun Y; Sanchez GA; Goldbach-Mansky R; Christiano AM; Clynes R; Zlotogorski A
EBioMedicine; 2015 Apr; 2(4):351-5. PubMed ID: 26137574
[TBL] [Abstract][Full Text] [Related]
92. Topical tofacitinib for the treatment of alopecia areata affecting facial hair.
Kerkemeyer KLS; Sinclair RD; Bhoyrul B
Br J Dermatol; 2021 Sep; 185(3):677-679. PubMed ID: 33914907
[No Abstract] [Full Text] [Related]
93. [Antineoplasic drug repurposing in hematology for COVID-19 treatment].
Tazi I
Bull Cancer; 2021 Apr; 108(4):435-437. PubMed ID: 33663776
[No Abstract] [Full Text] [Related]
94. The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Peterson D; Damsky W; King B
J Am Acad Dermatol; 2020 Jun; 82(6):e223-e226. PubMed ID: 32278797
[No Abstract] [Full Text] [Related]
95. Promising new treatments for rheumatoid arthritis - the kinase inhibitors.
Yazici Y; Regens AL
Bull NYU Hosp Jt Dis; 2011; 69(3):233-7. PubMed ID: 22035435
[TBL] [Abstract][Full Text] [Related]
96. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
Liu LY; Strassner JP; Refat MA; Harris JE; King BA
J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882
[TBL] [Abstract][Full Text] [Related]
97. [Anti-rheumatic effect of JAK-inhibitors].
Yamaoka K; Maeshima K; Kubo S; Sonomoto K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(2):112-7. PubMed ID: 22576568
[TBL] [Abstract][Full Text] [Related]
98. Efficacy of systemic minoxidil and tofacitinib combination in treatment-resistant alopecia universalis.
Dincer D; Tanacan E; Kose Ozkan C
J Cosmet Dermatol; 2021 Jun; 20(6):1807-1809. PubMed ID: 33098729
[TBL] [Abstract][Full Text] [Related]
99. Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions.
Fukuyama T; Tschernig T; Qi Y; Volmer DA; Bäumer W
Eur J Pharmacol; 2015 Oct; 764():278-282. PubMed ID: 26164790
[TBL] [Abstract][Full Text] [Related]
100. In the pipeline for psoriasis: upcoming psoriasis treatments.
Han G
Cutis; 2014 Mar; 93(3):E12-6. PubMed ID: 24738104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
